Opdualag

Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma.[1] It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody.[1] It is given by intravenous infusion.[1] The combination was approved for medical use in the United States in March 2022.[1][2] Referenc... [wikipedia]